Developmental Relationships of Four Exhausted CD8+ T Cell Subsets Reveals Underlying Transcriptional and Epigenetic Landscape Control Mechanisms

doi:10.1016/j.immuni.2020.04.014

. 2020 May 19;52(5):825-841.e8.

doi: 10.1016/j.immuni.2020.04.014. Epub 2020 May 11.

Developmental Relationships of Four Exhausted CD8⁺ T Cell Subsets Reveals Underlying Transcriptional and Epigenetic Landscape Control Mechanisms

Jean-Christophe Beltra¹, Sasikanth Manne², Mohamed S Abdel-Hakeem³, Makoto Kurachi⁴, Josephine R Giles¹, Zeyu Chen², Valentina Casella⁵, Shin Foong Ngiow¹, Omar Khan⁶, Yinghui Jane Huang², Patrick Yan⁶, Kito Nzingha², Wei Xu⁷, Ravi K Amaravadi⁷, Xiaowei Xu⁸, Giorgos C Karakousis⁹, Tara C Mitchell⁷, Lynn M Schuchter⁷, Alexander C Huang¹⁰, E John Wherry¹¹

Affiliations

¹ Department of Systems Pharmacology and Translational Therapeutics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA; Institute for Immunology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA; Parker Institute for Cancer Immunotherapy at University of Pennsylvania, Philadelphia, PA, USA.
² Department of Systems Pharmacology and Translational Therapeutics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA; Institute for Immunology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
³ Department of Systems Pharmacology and Translational Therapeutics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA; Institute for Immunology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA; Parker Institute for Cancer Immunotherapy at University of Pennsylvania, Philadelphia, PA, USA; Department of Microbiology and Immunology, Faculty of Pharmacy, Cairo University, Kasr El-Aini, Cairo, Egypt.
⁴ Department of Molecular Genetics, Graduate School of Medical Sciences, Kanazawa University, Kanazawa, Japan.
⁵ Infection Biology Laboratory, Department of Experimental and Health Sciences (DCEXS), Universitat Pompeu Fabra, Barcelona, Spain.
⁶ Department of Systems Pharmacology and Translational Therapeutics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA; Institute for Immunology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA; Arsenal Biosciences, South San Francisco, CA, USA.
⁷ Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA; Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
⁸ Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA; Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
⁹ Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA; Department of Surgery, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
¹⁰ Institute for Immunology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA; Parker Institute for Cancer Immunotherapy at University of Pennsylvania, Philadelphia, PA, USA; Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA; Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
¹¹ Department of Systems Pharmacology and Translational Therapeutics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA; Institute for Immunology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA; Parker Institute for Cancer Immunotherapy at University of Pennsylvania, Philadelphia, PA, USA. Electronic address: wherry@pennmedicine.upenn.edu.

PMID: 32396847
PMCID: PMC8360766
DOI: 10.1016/j.immuni.2020.04.014

Developmental Relationships of Four Exhausted CD8⁺ T Cell Subsets Reveals Underlying Transcriptional and Epigenetic Landscape Control Mechanisms

Jean-Christophe Beltra et al. Immunity. 2020.

. 2020 May 19;52(5):825-841.e8.

doi: 10.1016/j.immuni.2020.04.014. Epub 2020 May 11.

Authors

Affiliations

¹ Department of Systems Pharmacology and Translational Therapeutics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA; Institute for Immunology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA; Parker Institute for Cancer Immunotherapy at University of Pennsylvania, Philadelphia, PA, USA.
² Department of Systems Pharmacology and Translational Therapeutics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA; Institute for Immunology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
³ Department of Systems Pharmacology and Translational Therapeutics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA; Institute for Immunology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA; Parker Institute for Cancer Immunotherapy at University of Pennsylvania, Philadelphia, PA, USA; Department of Microbiology and Immunology, Faculty of Pharmacy, Cairo University, Kasr El-Aini, Cairo, Egypt.
⁴ Department of Molecular Genetics, Graduate School of Medical Sciences, Kanazawa University, Kanazawa, Japan.
⁵ Infection Biology Laboratory, Department of Experimental and Health Sciences (DCEXS), Universitat Pompeu Fabra, Barcelona, Spain.
⁶ Department of Systems Pharmacology and Translational Therapeutics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA; Institute for Immunology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA; Arsenal Biosciences, South San Francisco, CA, USA.
⁷ Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA; Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
⁸ Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA; Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
⁹ Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA; Department of Surgery, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
¹⁰ Institute for Immunology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA; Parker Institute for Cancer Immunotherapy at University of Pennsylvania, Philadelphia, PA, USA; Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA; Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
¹¹ Department of Systems Pharmacology and Translational Therapeutics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA; Institute for Immunology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA; Parker Institute for Cancer Immunotherapy at University of Pennsylvania, Philadelphia, PA, USA. Electronic address: wherry@pennmedicine.upenn.edu.

PMID: 32396847
PMCID: PMC8360766
DOI: 10.1016/j.immuni.2020.04.014

Abstract

CD8⁺ T cell exhaustion is a major barrier to current anti-cancer immunotherapies. Despite this, the developmental biology of exhausted CD8⁺ T cells (Tex) remains poorly defined, restraining improvement of strategies aimed at "re-invigorating" Tex cells. Here, we defined a four-cell-stage developmental framework for Tex cells. Two TCF1⁺ progenitor subsets were identified, one tissue restricted and quiescent and one more blood accessible, that gradually lost TCF1 as it divided and converted to a third intermediate Tex subset. This intermediate subset re-engaged some effector biology and increased upon PD-L1 blockade but ultimately converted into a fourth, terminally exhausted subset. By using transcriptional and epigenetic analyses, we identified the control mechanisms underlying subset transitions and defined a key interplay between TCF1, T-bet, and Tox in the process. These data reveal a four-stage developmental hierarchy for Tex cells and define the molecular, transcriptional, and epigenetic mechanisms that could provide opportunities to improve cancer immunotherapy.

Keywords: CD8; PD-1 blockade; T cell exhaustion lineage; T-bet; TCF1; Tox; cancer immunotherapy; chronic infection; epigenetics; exhaustion.

PubMed Disclaimer

Conflict of interest statement

Declaration of Interests E.J.W. is a member of the Parker Institute for Cancer Immunotherapy which supported these studies. E.J.W. has consulting agreements with and/or is on the scientific advisory board for Merck, Roche, Pieris, Elstar, and Surface Oncology. E.J.W. has a patent licensing agreement on the PD-1 pathway with Roche/Genentech. E.J.W. is a founder of Arsenal Biosciences.

Figures

**Figure 1.. Four Tex Subsets Develop during Chronic Viral Infections and Cancer**
Naive CD45.1⁺ P14 CD8⁺ T (10³) were adoptively transferred into C57BL/6J mice (CD45.2⁺) after infection with LCMV clone 13 and analyzed at d30pi. (A) Ly108 and TCF1 expression by PD-1^int and PD-1^hi P14 CD8⁺ T cells. Numbers are frequencies. (B) Representative Ki67 and CD69 co-expression in indicated populations of P14 CD8⁺ T cells. (C) Representative histograms for indicated markers on subpopulations among endogenous D^bgp33 tetramer⁺ CD8⁺ T cells. Numbers are mean fluorescence intensity (MFI). (D) Representative Ly108 and CD69 co-expression on splenic P14 CD8⁺ T cells at indicated time post-infection (pi) with LCMV Armstrong (left) or clone 13 (right). Numbers are frequencies. (E) Frequencies of different P14 populations at indicated time after clone-13 infection. (F) Absolute number of different P14 populations at indicated time after clone-13 infection. (G) Representative Ly108 and CD69 co-expression in tissues. Numbers are frequencies. (H) Frequencies of Ki67⁺ cells among indicated P14 populations (gray line; right axis) and MFI for TCF1 (blue line; left axis). (I) Representative TCF1 and CD69 co-expression on PD-1⁺Tox⁺ TILs from B16 tumors (see Figure S1I for gating). Right graph shows cumulative data. (J) Representative TCF1 and CD69 co-expression on non-naive Tox⁺ TILs (see Figure S1J for gating) analyzed from human melanoma tumors. n = 7 patients. (A)–(H), n = 5 with 6 to 16 mice per group/time point. (I), n = 2 with 11 mice/group.

**Figure 2.. Developmental Lineage Relationships between Four Tex Subsets and Changes upon PD-L1 Blockade**
(A) Experimental design. Tex subsets were sorted from endogenous PD-1⁺ CD8⁺ T cells at d21pi, labeled with CFSE, transferred back (1 × 10⁵ each) into infection-matched recipients and analyzed 7 days post-transfer (d28pi). (B) CFSE profile of indicated transferred populations. Numbers are frequencies. (C) Frequencies of P14 populations from indicated donor cells. (D) Ly108 and CD69 co-expression on divided (CFSE^lo) and undivided (CFSE^hi) cells that developed from indicated transferred cells. (E) Ratio of Ly108⁺CD69⁺/Ly108⁺CD69⁻ within CFSE^lo (light blue) and CFSE^hi (dark blue) cells from indicated donor origin. (F) IRs co-expression on indicated P14 populations. (G) Representative PD-1/CD44, Cxcr5/Tim-3, and T-bet/Eomes co-expression in indicated P14 populations. (H) Representative Ly108 and CD69 co-expression on P14 (CD45.1⁺) and endogenous D^bgp33⁺ (CD45.2⁺) CD8⁺ T cells 1 day after treatment (d35pi) with either PBS (CTR) or anti-PD-L1. (I) Absolute number of indicated P14 populations 1 day post-treatment (d35pi) with either PBS (CTR) or anti-PD-L1. (B)–(E), n = 2 with 6–8 mice/group; (F), n = 3 with 10 mice/group; (G), n = 2 with 9 mice/group; (H) and (I), n = 2 with 7–11 mice/group.

**Figure 3.. Developmental Transitions Alter Tex Subset Localization and Effector Functions**
(A) LCMV-clone-13-infected mice were injected with 3μg/mouse of anti-CD8 i.v. at d30pi and sacrificed 3 min later. Representative dot plots (left) and frequencies (right) of indicated P14 populations located either in the white pulp (CD8 i.v. antibody negative) or the red pulp (CD8 i.v. antibody positive) of the spleen. Numbers are frequencies. (B) Representative Ly108 and CD69 co-expression on P14 CD8⁺ T cells isolated from the spleen (left plot) or blood (right plot). Numbers are frequencies. (C) TCF1 expression in indicated P14 populations isolated from the blood. (D) Representative IFNγ and TNF co-production by indicated P14 populations at d30pi. Numbers are frequencies. (E–G) Frequencies of IFNγ+ (E), IFNγ+TNFα+ (F), and CD107a+ (G) cells among indicated P14 populations. (H) Representative CD107a expression by indicated P14 populations. Numbers are MFI. (I) Indicated P14 populations were sorted at d30pi, labeled with CFSE, and incubated with gp33-peptide coated dendritic cells (ratio 1/1). Dot plots display CFSE dilution profile after 3 days of co-culture. Numbers are frequencies. (J) Representative dot plots and frequencies of active caspase-3-positive cells within indicated P14 populations. Numbers are frequencies. (A)–(C), 3 independent experiments with 12–18 mice/group; (D)–(H), n = 2 with 7 mice/group; (I), n = 2 with 4–10 mice/group; (J), n = 3 with 10 mice/group.

**Figure 4.. Subset Transitions Induce Major Transcriptional Changes and Drive Acquisition of Population-Specific Transcriptomic Signatures**
(A) PCA of RNA-seq profiles. (B) Venn diagram displaying overlaps between DEGs from indicated pairwise comparisons (lfc ≥ 1, p = 0.01). (C) DEGs^UP overlaps between indicated P14 populations. Bubble size represents the proportion of DEGs^UP from each individual Tex population (y axis) also found to be upregulated in indicated Tex subsets (x axis) in at least one pairwise comparison. (D) Heatmap displaying all DEGs (lfc ≥ 1, p = 0.01) clustered by using Pearson correlation as distance measure. Color legend indicates row z scores. (E) Pathway enrichment analysis. Bubble graph displays the five most significantly enriched pathways by log(q-value) for each cluster established in Figure 4D. (F) Representative histograms showing the expression of indicated markers by different P14 populations. Numbers are MFIs. (G) GSEA displaying enrichment of each individual Tex subset for signatures of indicated cell types. NES, Normalized Enrichment Score. n = 3 biological replicates.

**Figure 5.. Epigenetic Remodeling during Tex Subset Transitions Identifies Subset-Specific TF Accessibility**
(A) ATAC-seq tracks at indicated loci. (B) PCA of normalized ATAC-seq counts (top 25% peaks by variance are displayed). (C) Spearman correlation network analysis showing similarities between indicated populations based on all ATAC-seq peaks. (D) Heatmap of peak intensity displaying the top 500 peaks by variance and clustered by using K-means method (k = 5). Color legend indicates row z scores. (E) Number of statistically significant peaks (lfc ≥ 1, p < 0.05) either opening (red) or closing (blue) upon indicated subset transitions. (F) Alluvial plot displaying the dynamics of transition-specific peaks (E) and refined as lfc ≥ 1, p < 0.01. (G) TF motifs enrichment analysis (HOMER) of subset-transition specific peaks (E). Volcano plots show TFs with the highest predicted binding activity to the identified DNA sequence. (H) Comparing TF motif enrichment with differential mRNA expression (Log2FoldChange) upon the indicated subset-transition. Plotted are TFs with a motif enrichment fold over background >1.25 in (G). (I) Protein expression dynamics of TCF1 and T-bet in the indicated P14 populations at d30pi. (A)–(H), n = 3 biological replicates; (I), n = 2 with 7mice/group.

**Figure 6.. TCF1 and T-bet Mediate Opposing Regulation of Tex Subset Differentiation**
(A) Experimental design. (B) Representative flow cytometry plots (left) and frequencies (right) of indicated populations among splenic WT (gray; open circles) or TCF1KO (blue) P14 CD8⁺ T cells at d8pi. Numbers are frequencies. (C–F) Gating strategy, representative flow cytometry plots and frequencies of indicated populations of WT P14 (gray; open bars) or T-bet KO P14 (blue) at d8 ([C] and [D]) and 15 ([E] and [F]) pi. Numbers are frequencies. (G) Representative Ly108 and CD69 co-expression by P14 CD8⁺ T cells transduced (VEX+; lower line) or not (VEX−; upper line) with either empty (Empty RV), TCF1 (short isoform; TCF1 RV), or T-bet (Tbet RV) encoding RVs at d15pi. Numbers are frequencies. (B), n = 2 with 7 mice/group; (C)–(F), n = 3–5 with 11–17 mice/group; (G), n = 1 with 4 mice/group.

**Figure 7.. Tox Modulates Tex Subset Dynamics through Regulation of T-bet**
(A) Tox MFI (blue line; left axis) and Tox/T-bet ratio (gray bars; right axis) in indicated populations among D^bgp33 tetramer⁺CD8⁺ T cells at d27pi. (B) Representative T-bet and Tox co-expression in PD-1⁺ D^bgp33 tetramer⁺ CD8⁺ T cells at d27pi. (C) Representative plots (left) and frequency (right) of indicated populations among Tox^int (gray) and Tox^hi (blue) endogenous D^bgp33 tetramer⁺ CD8⁺ T cells. (D) T-bet MFI in Tox^int and Tox^hi endogenous D^bgp33 tetramer⁺ CD8⁺ T cells. (E and F) T-bet (E) and Tox (F) MFI in indicated populations (gated on TCF1 and CD69; Figure 1J) within non-naive Tox⁺ TILs isolated from human melanoma tumors. (G) ATACseq tracks at the *Tbx21* locus highlighting TFs with predictive binding sites at the indicated OCRs. (H) Correlation score by mRNA between T-bet and TFs predicted to bind near the *Tbx21* locus (filtering out TFs without detectable mRNA in Tex subsets). Each TF is colored by the cell-type in which mRNA expression is highest (red-Tex^prog1, orange Tex^prog2, green-Tex^int, blue-Tex^term). (I) Experimental design. (J) Numbers of Tox^+/+ P14 (gray) and Tox^+/− P14 (blue) cells at the indicated time points. (K) Representative dot plots (left) and frequencies (right) of the indicated populations among Tox^+/+ (gray; open circles) and Tox^+/− (blue) P14 cells. Numbers indicate frequencies. Numbers in the histogram are MFI. (L) Number of indicated populations within Tox^+/+ P14 (gray) and Tox^+/− P14 (blue) at d27pi. (M) T-bet MFI in indicated populations among Tox^+/+ P14 (open circles) and Tox^+/− P14 (blue circles). Linked circles represent individual mice. (A)–(D), 3 experiments with 22 mice/group; (E) and (F), n = 7 patients; (J)–(M), 2 experiments with 15 mice/group.

See this image and copyright information in PMC

Comment in

Charting the Roadmap of T Cell Exhaustion.
Chu T, Zehn D. Chu T, et al. Immunity. 2020 May 19;52(5):724-726. doi: 10.1016/j.immuni.2020.04.019. Immunity. 2020. PMID: 32433943

Cited by

Inhibitory Fcγ receptor deletion enhances CD8 T cell stemness increasing anti-PD-1 therapy responsiveness against glioblastoma.
Ku KB, Kim CW, Kim Y, Kang BH, La J, Kang I, Park WH, Ahn S, Lee SK, Lee HK. Ku KB, et al. J Immunother Cancer. 2024 Oct 26;12(10):e009449. doi: 10.1136/jitc-2024-009449. J Immunother Cancer. 2024. PMID: 39461881 Free PMC article.
Immunogenicity and toxicity of AAV gene therapy.
Ertl HCJ. Ertl HCJ. Front Immunol. 2022 Aug 12;13:975803. doi: 10.3389/fimmu.2022.975803. eCollection 2022. Front Immunol. 2022. PMID: 36032092 Free PMC article. Review.
Technology meets TILs: Deciphering T cell function in the -omics era.
Hudson WH, Wieland A. Hudson WH, et al. Cancer Cell. 2023 Jan 9;41(1):41-57. doi: 10.1016/j.ccell.2022.09.011. Epub 2022 Oct 6. Cancer Cell. 2023. PMID: 36206755 Free PMC article. Review.
Exploring potential predictive biomarkers through historical perspectives on the evolution of systemic therapies into the emergence of neoadjuvant therapy for the treatment of hepatocellular carcinoma.
Wang C, Wei F, Sun X, Qiu W, Yu Y, Sun D, Zhi Y, Li J, Fan Z, Lv G, Wang G. Wang C, et al. Front Oncol. 2024 Jun 27;14:1429919. doi: 10.3389/fonc.2024.1429919. eCollection 2024. Front Oncol. 2024. PMID: 38993637 Free PMC article. Review.
The architectural design of CD8+ T cell responses in acute and chronic infection: Parallel structures with divergent fates.
Chung HK, McDonald B, Kaech SM. Chung HK, et al. J Exp Med. 2021 Apr 5;218(4):e20201730. doi: 10.1084/jem.20201730. J Exp Med. 2021. PMID: 33755719 Free PMC article. Review.

See all "Cited by" articles

References

1. Alfei F, Kanev K, Hofmann M, Wu M, Ghoneim HE, Roelli P, Utzschneider DT, von Hoesslin M, Cullen JG, Fan Y, et al. (2019). TOX reinforces the phenotype and longevity of exhausted T cells in chronic viral infection. Nature 571, 265–269. - PubMed
1. Anderson KG, Mayer-Barber K, Sung H, Beura L, James BR, Taylor JJ, Qunaj L, Griffith TS, Vezys V, Barber DL, and Masopust D (2014). Intravascular staining for discrimination of vascular and tissue leukocytes. Nat. Protoc 9, 209–222. - PMC - PubMed
1. Beltra JC, Bourbonnais S, Bédard N, Charpentier T, Boulangé M, Michaud E, Boufaied I, Bruneau J, Shoukry NH, Lamarre A, and Decaluwe H (2016). IL2Rβ-dependent signals drive terminal exhaustion and suppress memory development during chronic viral infection. Proc. Natl. Acad. Sci. USA 113, E5444–E5453. - PMC - PubMed
1. Bengsch B, Ohtani T, Khan O, Setty M, Manne S, O’Brien S, Gherardini PF, Herati RS, Huang AC, Chang KM, et al. (2018). Epigenomic-Guided Mass Cytometry Profiling Reveals Disease-Specific Features of Exhausted CD8 T Cells. Immunity 48, 1029–1045.e5, e1025. - PMC - PubMed
1. Berrien-Elliott MM, Yuan J, Swier LE, Jackson SR, Chen CL, Donlin MJ, and Teague RM (2015). Checkpoint blockade immunotherapy relies on T-bet but not Eomes to induce effector function in tumor-infiltrating CD8+ T cells. Cancer Immunol. Res 3, 116–124. - PMC - PubMed

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Grants and funding

LinkOut - more resources

Full Text Sources
Other Literature Sources
- The Lens - Patent Citations Database
Molecular Biology Databases
- Mouse Genome Informatics (MGI)
- NIAID Data Ecosystem - Find datasets on Infectious and Immune-mediated Diseases
Research Materials
- NCI CPTC Antibody Characterization Program

[1] Alfei F, Kanev K, Hofmann M, Wu M, Ghoneim HE, Roelli P, Utzschneider DT, von Hoesslin M, Cullen JG, Fan Y, et al. (2019). TOX reinforces the phenotype and longevity of exhausted T cells in chronic viral infection. Nature 571, 265–269. - PubMed

[2] Alfei F, Kanev K, Hofmann M, Wu M, Ghoneim HE, Roelli P, Utzschneider DT, von Hoesslin M, Cullen JG, Fan Y, et al. (2019). TOX reinforces the phenotype and longevity of exhausted T cells in chronic viral infection. Nature 571, 265–269. - PubMed

[3] Anderson KG, Mayer-Barber K, Sung H, Beura L, James BR, Taylor JJ, Qunaj L, Griffith TS, Vezys V, Barber DL, and Masopust D (2014). Intravascular staining for discrimination of vascular and tissue leukocytes. Nat. Protoc 9, 209–222. - PMC - PubMed

[4] Anderson KG, Mayer-Barber K, Sung H, Beura L, James BR, Taylor JJ, Qunaj L, Griffith TS, Vezys V, Barber DL, and Masopust D (2014). Intravascular staining for discrimination of vascular and tissue leukocytes. Nat. Protoc 9, 209–222. - PMC - PubMed

[5] Beltra JC, Bourbonnais S, Bédard N, Charpentier T, Boulangé M, Michaud E, Boufaied I, Bruneau J, Shoukry NH, Lamarre A, and Decaluwe H (2016). IL2Rβ-dependent signals drive terminal exhaustion and suppress memory development during chronic viral infection. Proc. Natl. Acad. Sci. USA 113, E5444–E5453. - PMC - PubMed

[6] Beltra JC, Bourbonnais S, Bédard N, Charpentier T, Boulangé M, Michaud E, Boufaied I, Bruneau J, Shoukry NH, Lamarre A, and Decaluwe H (2016). IL2Rβ-dependent signals drive terminal exhaustion and suppress memory development during chronic viral infection. Proc. Natl. Acad. Sci. USA 113, E5444–E5453. - PMC - PubMed

[7] Bengsch B, Ohtani T, Khan O, Setty M, Manne S, O’Brien S, Gherardini PF, Herati RS, Huang AC, Chang KM, et al. (2018). Epigenomic-Guided Mass Cytometry Profiling Reveals Disease-Specific Features of Exhausted CD8 T Cells. Immunity 48, 1029–1045.e5, e1025. - PMC - PubMed

[8] Bengsch B, Ohtani T, Khan O, Setty M, Manne S, O’Brien S, Gherardini PF, Herati RS, Huang AC, Chang KM, et al. (2018). Epigenomic-Guided Mass Cytometry Profiling Reveals Disease-Specific Features of Exhausted CD8 T Cells. Immunity 48, 1029–1045.e5, e1025. - PMC - PubMed

[9] Berrien-Elliott MM, Yuan J, Swier LE, Jackson SR, Chen CL, Donlin MJ, and Teague RM (2015). Checkpoint blockade immunotherapy relies on T-bet but not Eomes to induce effector function in tumor-infiltrating CD8+ T cells. Cancer Immunol. Res 3, 116–124. - PMC - PubMed

[10] Berrien-Elliott MM, Yuan J, Swier LE, Jackson SR, Chen CL, Donlin MJ, and Teague RM (2015). Checkpoint blockade immunotherapy relies on T-bet but not Eomes to induce effector function in tumor-infiltrating CD8+ T cells. Cancer Immunol. Res 3, 116–124. - PMC - PubMed

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Developmental Relationships of Four Exhausted CD8⁺ T Cell Subsets Reveals Underlying Transcriptional and Epigenetic Landscape Control Mechanisms

Affiliations

Developmental Relationships of Four Exhausted CD8⁺ T Cell Subsets Reveals Underlying Transcriptional and Epigenetic Landscape Control Mechanisms

Authors

Affiliations

Abstract

Conflict of interest statement

Figures

Comment in

Similar articles

Cited by

References

Publication types

MeSH terms

Substances

Grants and funding

LinkOut - more resources

Full Text Sources

Other Literature Sources

Molecular Biology Databases

Research Materials

Abstract

Conflict of interest statement

Figures

Comment in

Similar articles

Cited by

References

Publication types

MeSH terms

Substances

Related information

Grants and funding

LinkOut - more resources

Full Text Sources

Other Literature Sources

Molecular Biology Databases

Research Materials